Skip to main content
. 2023 Jul 13;29(18):3622–3632. doi: 10.1158/1078-0432.CCR-23-0276

Table 2.

Adverse events across all dose levels and cycles (regardless of attribution) occurring in more than 10% of patients or grade 3 or higher events.

Adverse event term Grade 1–2, n (%) Grade 3–4, n (%) All grades, n (%)
Hematologic Anemia 1 6 7 (33%)
Platelet count decreased 3 4 7 (33%)
Neutrophil count decreased 3 3 (14%)
White blood cell decreased 2 2 (10%)
Leukocytosis 1 1 2 (10%)
Nonhematologic Pruritus 9 9 (43%)
Fatigue 7 1 8 (38%)
Abdominal pain 7 7 (33%)
Diarrhea 6 6 (29%)
Edema limbs 5 5 (24%)
Nausea 5 5 (24%)
Epistaxis 4 1 5 (24%)
Hyperuricemia 5 5 (24%)
Gastrointestinal disorders 2 2 4 (19%)
Creatinine increased 4 4 (19%)
AST increased 3 3 (14%)
Pain 4 4 (19%)
Dizziness 4 4 (19%)
Cough 3 3 (14%)
Dyspnea 3 3 (14%)
Hypomagnesmia 3 3 (14%)
Hypocalcemia 2 1 3 (14%)
Headache 3 3 (14%)
Muscle cramps 3 3 (14%)
Anorexia 3 3 (14%)
Hyponatremia 3 3 (14%)
Vomiting 3 3 (14%)
Palpitations 3 3 (14%)
Rash maculopapular 2 1 3 (14%)
Mucositis 2 1 3 (14%)
Urinary tract infection 1 1 2 (10%)
Duodenal hemorrhage 1 1 (5%)
Gastric hemorrhage 1 1 (5%)
Extraocular muscle paresis 1 1 (5%)
Syncope 1 1 (5%)